RDH094

RDH094 is a small molecule, oral extended-release tablet developed by Apichope Pharmaceutical (Guangzhou Apichope Pharmaceutical Co., Ltd.) for the treatment of musculoskeletal system diseases. Currently in the preclinical stage of development, RDH094 is classified as a Class 2.2 improved new drug in China. This classification typically refers to a new dosage form or formulation of an existing drug that offers clinical advantages, such as improved efficacy, safety, or patient compliance. While the specific active pharmaceutical ingredient and molecular target have not been publicly disclosed, the drug is part of Apichope's expanding portfolio in the musculoskeletal therapeutic area.

Other names

RDH094 extended-release tabletRDH-094 extended-release tabletRDH 094 extended-release tablet